Role of Adiposomes in Endothelial Dysfunction
Launched by UNIVERSITY OF ILLINOIS AT CHICAGO · Jan 5, 2022
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how certain tiny particles, called adiposomes, released from fat tissue might contribute to blood vessel problems in people with obesity and type II diabetes. Researchers believe that these adiposomes carry unhealthy fats that can disrupt the normal function of blood vessels, which is a risk factor for heart disease. The trial aims to understand how these particles work and whether lifestyle changes like exercise and weight loss can help improve blood vessel health in these patients.
To participate, you need to be between 18 and 50 years old, have a body mass index (BMI) of 35 or higher, and be diabetic. You should also be cleared by a doctor to participate in moderate exercise. Unfortunately, individuals who are pregnant, smoke, or have certain health conditions like chronic diseases or a history of severe allergic reactions to lidocaine are not eligible. Participants in the trial can expect to engage in exercise programs and may undergo tests to see how their blood vessels respond to these adiposomes and the impact of their lifestyle changes. This research could lead to better ways to manage heart health in people dealing with obesity and diabetes.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • BMI ≥ 35 kg/m2
- • Between ages 18-50 years
- • Not pregnant
- • Diabetic (Current use of diabetes medication or fasting glucose ≥126 mg/dL)
- • Medical clearance to participate in a moderate-intensity exercise program
- Exclusion Criteria:
- • Pregnant women
- • Current smokers
- • Currently abusing alcohol or drugs
- • Chronic heart, liver, or kidney diseases, autoimmune diseases, or cancer
- • Non-English speakers
- • History of allergic reactions to lidocaine
About University Of Illinois At Chicago
The University of Illinois at Chicago (UIC) is a leading academic institution renowned for its commitment to advancing health sciences through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, UIC harnesses the expertise of its diverse faculty and state-of-the-art facilities to conduct cutting-edge clinical studies aimed at improving patient outcomes. The university's robust infrastructure for clinical research, combined with its dedication to ethical standards and regulatory compliance, positions UIC as a pivotal contributor to the development of new treatments and therapies in various medical fields. Through strategic partnerships and community engagement, UIC strives to translate research findings into real-world applications, enhancing the health and well-being of populations locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chicago, Illinois, United States
Patients applied
Trial Officials
Abeer M Mohamed, MD, PhD
Principal Investigator
University of Illinois at Chicago
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials